India Next-Generation Oncology Devices and Solutions Market Size, Share & Forecast, By Product Type, Care Setting & Technology, 2025-2032

The India Next-Generation Oncology Devices and Solutions Market is worth USD 1,340 million in 2025. The market includes advanced oncology-specific diagnostics, radiation oncology systems, image-guided intervention platforms, digital oncology software, specialized molecular tools, and associated recurring technology revenues. It excludes oncology drugs, general hospital-service revenue, routine imaging unrelated to oncology workflows, and unrelated pathology activity. Demand is supported by an estimated 1.57 million incident cancer cases in 2025 and a widening network of cancer-care institutions, laboratories, and advanced treatment facilities.

The market is projected to reach USD 3,000 million by 2032, representing a 12.20% CAGR during 2025-2032. Growth is expected to be supported by precision diagnostics, adaptive radiotherapy, AI-enabled imaging, digital pathology, genomics, and oncology informatics. Procedure and testing activity is expected to expand faster than effective price and mix in later forecast years as installed systems achieve higher utilization and localization becomes more meaningful. The forecast therefore reflects both access expansion and deeper technology intensity within existing cancer-care institutions.

Incremental profit pools should shift toward molecular assays, companion diagnostics, bioinformatics, software subscriptions, maintenance, upgrades, clinical applications, and workflow integration. Capital equipment remains essential, but each installed system increasingly functions as a platform for recurring monetization. The modeled advanced procedure and test volume index rises from 100 in 2025 to 236.9 in 2032, indicating substantial utilization expansion. Vendors connecting diagnostics, treatment planning, delivery, and monitoring can therefore generate stronger account economics and customer retention than businesses relying primarily on periodic equipment replacements.

The largest structural risk is the combination of capital-intensive treatment infrastructure and continued dependence on imported high-end technology. A radiotherapy infrastructure assessment identified 823 functioning machines against materially higher estimated need, producing a shortfall of 1,209 machines. Broader medical-device imports still represent around 60% of domestic consumption. These conditions expose providers and vendors to financing constraints, currency movements, imported spare parts, service logistics, installation delays, and regulatory complexity, particularly for radiation systems and higher-risk devices requiring specialized approvals and trained technical personnel.

India ranks third in the selected peer comparison by modeled 2025 market value, behind China and Japan and ahead of South Korea and Australia. India nevertheless has the highest modeled forecast CAGR in the peer set at 12.20%. Its opportunity is created by the combination of a large cancer workload and relatively low advanced-treatment infrastructure density. Comparable radiation-therapy equipment data show India at roughly 0.7 units per million population, versus 10.1 in Japan and 11.8 in Australia, highlighting both an infrastructure constraint and long-term expansion opportunity.

The most important demand factor is expansion of diagnosed and treated cancer workload across a broader institutional network. Projected incident cases reach about 1.57 million in 2025, increasing requirements for pathology, molecular profiling, staging, radiotherapy planning, intervention, and monitoring. At the same time, 524 Day Care Cancer Centres were operating by July 2026, widening the referral network feeding tertiary hospitals and laboratories. Technology suppliers therefore need hub-and-spoke offerings connecting decentralized screening and day-care capacity with high-complexity diagnostic and treatment infrastructure rather than concentrating solely on metropolitan capital sales.